Acute myeloid leukemia (AML) is an aggressive disorder that develops throughout life but is commonly encountered in individuals above the age of 60 years. Unfortunately, despite intensive treatment strategies the prognosis of the majority of patients with AML is still dismal.
Within the "Myeloid Cells & Leukemia" group, researchers aim to identify novel pathogenetic mechanisms in AML and other myeloid neoplasms. We are interested in understanding mechanisms of myeloid leukemogenesis and identifying critical molecular aberrations as targets for novel leukemia therapies that will translate into improved patient outcome. Our location within a tertiary care cancer center has enabled us to establish a large collection of primary leukemia specimens. Furthermore, access to outstanding research facilities within the Medical University of Graz allows us to employ state-of-the-art leukemic cell culture and mouse models. The research group comprises independent investigators who share their expertise with biologists, medical scientists, students and technicians.
In addition to basic science, team members are conducting a series of clinical trials enabling patients with myeloid disorders access to innovative drugs and therapeutic approaches.